FINWIRES · TerminalLIVE
FINWIRES

$BIIB

53 stories mentioning BIIBUpdated 19d ago

Every FINWIRES story that references BIIB, newest first.

What are analysts saying about BIIB?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on BIIB?

Sectors

Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday

Healthcare stocks were edging higher premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly advancing and the iShares Biotechnology ETF (IBB) up 0.2%.Immatics (IMTX) shares were up more than 13% after the company said it has agreed to sell about 12.9 million ordinary shares at $8.69 each, and in lieu of ordinary shares to certain investors, pre-funded warrants to buy up to approximately 4.3 million ordinary shares at $8.689 per pre-funded warrant.Veeva Systems (VEEV) has signed Biogen (BIIB) and Regeneron Pharmaceuticals (REGN) as new users for its Veeva Vault CRM platform, according to statements from Veeva. Shares of Veeva Systems were down 0.1% premarket.Bausch + Lomb (BLCO) stock was up more than 1% after the company said it plans to advance two of its pharmaceutical pipeline assets to new trials based on latest clinical results.

$BIIB$BLCO$IBB$IMTX$REGN$VEEV$XLV
Research

Wolfe Upgrades Biogen to Outperform From Peer Perform, Price Target is $300

Biogen (BIIB) has an average rating of overweight and mean price target of $239.63, according to analysts polled by FactSet.

$BIIB
Wire

Mizuho Adjusts Price Target on Biogen to $241 From $221

Biogen (BIIB) has an average rating of overweight and mean price target of $236.24, according to analysts polled by FactSet.Price: $203.14, Change: $+0.19, Percent Change: +0.09%

$BIIB
Wire

BMO Capital Adjusts Price Target on Biogen to $208 From $196, Maintains Market Perform Rating

Biogen (BIIB) has an average rating of overweight and mean price target of $235.72, according to analysts polled by FactSet.Price: $204.33, Change: $-4.90, Percent Change: -2.34%

$BIIB
Wire

TD Cowen Adjusts Price Target on Biogen to $225 From $215, Maintains Buy Rating

Biogen (BIIB) has an average rating of overweight and mean price target of $235.72, according to analysts polled by FactSet.Price: $204.20, Change: $-5.03, Percent Change: -2.40%

$BIIB
Wire

BMO Raises Price Target on Biogen to $208 From $196, Keeps Market Perform Rating

Biogen (BIIB) has an average rating of overweight and mean price target of $235.24, according to analysts polled by FactSet.Price: $206.33, Change: $-2.91, Percent Change: -1.39%

$BIIB
Wire

JPMorgan Lifts Biogen Price Target to $210 From $185

Biogen (BIIB) has an average rating of overweight and mean price target of $230.32, according to analysts polled by FactSet.Price: $207.41, Change: $+1.80, Percent Change: +0.88%

$BIIB
Wire

Wedbush Adjusts Biogen Price Target to $215 From $201, Maintains Neutral Rating

Biogen (BIIB) has an average rating of overweight and mean price target of $230.32, according to analysts polled by FactSet.Price: $210.62, Change: $+5.01, Percent Change: +2.43%

$BIIB
Wire

Stifel Nicolaus Adjusts Biogen Price Target to $242 From $214

Biogen (BIIB) has an average rating of overweight and mean price target of $230.32, according to analysts polled by FactSet.Price: $211.30, Change: $+5.69, Percent Change: +2.77%

$BIIB
Wire

Biogen's Q2 Results Beat Boosted By Apellis Acquisition, Wedbush Says

Biogen's (BIIB) Q2 results beat was supported by the company's recent acquisition of Apellis, Wedbush Securities said in a note Wednesday.Biogen's Q2 total revenue of $2.736 billion was higher than consensus estimates at $2.462 billion as the company's product revenue included about $208 million in Apellis-linked revenue, the note said.Wedbush noted that after the acquisition, Biogen lowered its 2026 non-GAAP earnings per share guidance to $12.00 to $13.00 from the previous guidance of $14.25 to $15.25, partly reflecting a negative impact from Apellis charges, the note said.Wedbush said, however, the Q2 beat was a positive factor for the stock, while the guidance revision after the Apellis deal "seems as anticipated.""With management continuing to indicate accretion in 2027, we think this should be reassuring," the note said, with unlocking additional revenue growth drivers most important.Wedbush kept its neutral rating on Biogen and has a $201 price target on the company.Price: $216.33, Change: $+10.72, Percent Change: +5.21%

$BIIB
Wire

Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206

Biogen (BIIB) has an average rating of overweight and mean price target of $224.10, according to analysts polled by FactSet.Price: $191.24, Change: $-17.80, Percent Change: -8.51%

$BIIB
Wire

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday.As of July 6, the NYSE Arca Pharmaceutical Index has gained 11% and the Nasdaq Biotechnology Index has added 18%, compared with a 10% gain for the S&P 500 Index, with recent stock performance driven more by changes in valuation multiples than by earnings estimate revisions, the investment bank said.Morgan Stanley said its US Equity Strategy team expects the sector to benefit from broader market leadership. Biotech remains one of the most rate-sensitive sectors, and historically, the sector has delivered nearly 20% annualized returns during falling-rate environments, according to the note.In addition, merger and acquisition activity remains healthy, with several $5 billion to $10 billion deals recently announced, including AbbVie (ABBV) purchasing Apogee (APGE), and Vertex Pharmaceuticals (VRTX) buying Crinetics Pharmaceuticals (CRNX), the investment bank said.Morgan Stanley adjusted its price targets on Biogen (BIIB) to $222 from $224, Amgen (AMGN) to $333 from $340, Gilead Sciences (GILD) to $166 from $168, AbbVie to $279 from $278, Moderna (MRNA) to $39 from $33, BioNTech (BNTX) to $119 from $126, Regeneron Pharmaceuticals (REGN) to $730 from $788, Johnson & Johnson (JNJ) to $284 from $283, and Eli Lilly (LLY) to $1,347 from $1,344.Shares of Biogen, Amgen, Gilead, AbbVie, Moderna, BioNTech, Regeneron, Johnson & Johnson, and Eli Lilly were down 2%, 0.1%, 0.8%, 0.4%, 7%, 1.9%, 1.9%, 0.4%, and 0.5% respectively, in Wednesday trading.Price: $201.67, Change: $-4.03, Percent Change: -1.96%

$ABBV$AMGN$APGE$BIIB$BNTX$CRNX$GILD$JNJ$LLY$MRNA$REGN$VRTX
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks fell late Thursday afternoon with the NYSE Healthcare Index dropping 1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.9%.The iShares Biotechnology ETF (IBB) shed 0.3%.In corporate news, Pfizer (PFE) shares dropped 2.5% after the company reaffirmed its fiscal 2026 guidance. The company also said Chief Financial Officer Dave Denton will step down on Aug. 15 after accepting a position in the consumer-goods sector.Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion. Biogen shares fell 1.4%.EnGene (ENGN) shares shed 1.4% after Morgan Stanley downgraded the stock to underweight from equalweight.NovoCure (NVCR) shares tumbled 19% after the company said a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.

$BIIB$ENGN$NVCR$PFE
Sectors

Sector Update: Healthcare Stocks Decline Thursday Afternoon

Healthcare stocks fell Thursday afternoon with the NYSE Healthcare Index decreasing 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) declining 0.8%.The iShares Biotechnology ETF (IBB) shed 0.5%.In corporate news, Pfizer (PFE) shares fell 2.6% after the company said Chief Financial Officer Dave Denton will step down on Aug. 15 after accepting a position in the consumer-goods sector.Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion. Biogen shares fell 1.9%.NovoCure (NVCR) shares dropped 19% after the company said a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.Kardigan (KARD) shares surged 28% to $20.50 in their debut on the Nasdaq. The clinical-stage precision therapeutics company priced its initial public offering of 25 million shares at $16 each. Underwriters were granted a 30-day option to purchase an additional 3.75 million shares.

$BIIB$KARD$NVCR$PFE
Sectors

Sector Update: Healthcare

Healthcare stocks fell Thursday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each declining 1%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion. Biogen shares fell 2%.

$BIIB
Biogen to Acquire RayThera in Up to $1 Billion Deal to Expand Immunology Pipeline
US Markets

Biogen to Acquire RayThera in Up to $1 Billion Deal to Expand Immunology Pipeline

Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion as the firm aims to strengthen its immunology portfolio.Shareholders of RayThera, which develops small-molecule therapies in immunology, will receive an upfront payment from Biogen, according to a late Wednesday joint statement by the companies. The shareholders will also be eligible to receive certain clinical and regulatory milestone payments in the future, the companies said.Biogen's stock was up 0.5% in Thursday's premarket activity, having closed the previous session with a 1.6% gain.RayThera's portfolio includes several anti-inflammatory assets to potentially treat immune-mediated conditions. The firm's lead candidate is expected to enter phase 1 development early in the third quarter."With this acquisition, we are further deepening our pipeline in immunology by adding a suite of assets that can allow us to expand into new disease areas," Biogen's head of development, Priya Singhal, said. "We believe these assets can meaningfully contribute to our long-term pipeline potential and we're excited about the opportunity to rapidly advance the first candidate into the clinic."The transaction, which requires approval from regulators, is expected to complete in the third quarter. Following completion, Biogen intends to lead the development, manufacturing and global commercialization of RayThera's assets."With its strong global development capabilities in immunology, we believe that Biogen is the natural fit to move these assets forward into phase 1 development and beyond," according to RayThera Chief Executive Qing Dong.In March, Biogen agreed to purchase biopharmaceutical firm Apellis Pharmaceuticals (APLS), strengthening its immunology and rare disease portfolio and accelerating its expansion into nephrology. The deal had a total cash consideration of $5.6 billion.

$BIIB
Research

Needham Upgrades Biogen to Buy From Hold, Price Target is $255

Biogen (BIIB) has an average rating of overweight and mean price target of $219.86, according to analysts polled by FactSet.

$BIIB
Sectors

Sector Update: Healthcare Stocks Rise Premarket Thursday

Healthcare stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.5% higher and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Biogen (BIIB) shares were up more than 1% after the company said the US Food and Drug Administration has granted breakthrough therapy designation for Salanersen to treat spinal muscular atrophy, a rare, genetic and neuromuscular disease.Royal Philips (PHG) and WellSpan Health said they have entered into a seven-year partnership focused on research, innovation, and the deployment of advanced imaging and diagnostic technologies across WellSpan's network. Shares of Royal Philips were up more than 1% pre-bell.Amneal Pharmaceuticals (AMRX) stock was 1% higher after the company said has received the US Food and Drug Administration's approval for its romidepsin injection solution.

$AMRX$BIIB$IBB$PHG$XLV
Sectors

Sector Update: Health Care

Healthcare stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.5% higher and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Biogen (BIIB) shares were up more than 1% after the company said the US Food and Drug Administration has granted breakthrough therapy designation for Salanersen to treat spinal muscular atrophy, a rare, genetic and neuromuscular disease.

$BIIB
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Friday

Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.6% higher and the iShares Biotechnology ETF (IBB) down 0.1%.Biogen (BIIB) and Denali Therapeutics (DNLI) are discontinuing further development of BIIB122 in idiopathic Parkinson's disease after a phase 2b study failed to meet its primary or secondary endpoints, the companies said. Biogen shares were down 1% and Denali Therapeutics stock lost more than 3% pre-bell.Medline (MDLN) shares were up more than 1% after the company priced its upsized secondary offering of about 72.6 million of its class A shares on behalf of certain selling stockholders at $37 apiece.Gilead Sciences (GILD) said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion supporting approval of Trodelvy as a first-line treatment for certain patients with metastatic triple-negative breast cancer. Gilead Sciences shares were 0.4% higher pre-bell.

$BIIB$DNLI$GILD$IBB$MDLN$XLV

Showing 1-20 of 53

Track with the FINWIRES app suite

FolioX
FolioX
Track BIIB in your portfolio
WheelAI
WheelAI
Analyze BIIB options with the wheel strategy
StockInsider
StockInsider
See market sentiment on BIIB